Keros Therapeutics Inc (KROS)

SG&A Expense Growth

-15.19%

Quarterly · Period ending:

KROS logo

KROS SG&A Expense Growth

Latest reported-15.19%
KROS Quarterly SG&A Growth (QoQ) (0.00% → -15.19%)
High-resolution chart · PNG

KROS sg&a expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Keros Therapeutics Inc SG&A Expense Growth — Quarterly
Period endingSG&A Expense Growth
-15.1868%
-13.5911%
15.9573%
-30.0718%
37.9632%
-1.5752%
8.6049%
-1.4155%
-3.3663%
13.2125%
5.909%
-2.3401%
13.1782%
9.6574%
2.2488%
-6.8484%
23.1316%
5.5313%
6.822%
-5.1785%
32.3818%
18.1642%
1.8013%
-2.6575%
84.6232%
85.2858%
9.7737%
48.6239%
33.1976%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.